𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cohort Maintenance and Comparability in a Pharmacoepidemiologic Study Using a Commercial Consumer Panel to Recruit Comparators

✍ Scribed by Jacqueline S. Gardner; Cheryl A. Szpunar; Martin J. O'Connell; David P. Facklam; Joseph P. Mariano; E. Keith Borden; Frank B. Leinweber


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
609 KB
Volume
5
Category
Article
ISSN
1053-8569

No coin nor oath required. For personal study only.

✦ Synopsis


The Upjohn Consumer Health Survey (UCHS) was a prospective, observational study of users of ROGAINE'' (REGAINETM in international markets) Topical Solution 2% ( N = 11,122) and a Comparator cohort ( N = 11,173) which was selected and group matched by stratified random sampling from among members of a commercial consumer panel. Study endpoints were confirmed cause-specific deaths and hospitalizations within 12 months of study entry. Data collection was accomplished by participant interviews and confirmation of participant-reported medical events. At least 94% of both cohorts completed 12 months of follow-up, with the completion rate highest in the Comparator cohort (96.8%). Although successful matching was achieved on the demographic variables used to select the Comparators, members of the two cohorts differed significantly in the presence of baseline chronic medical conditions and other risk factors for study endpoints. A commercial consumer panel is valuable for rapid selection of demographically-matched comparators for targeted cohorts which continue in the study through long-term follow-up. Multi-stage sampling may need to be employed when more specific characteristics must be identified.


📜 SIMILAR VOLUMES


Use of a commercial consumer panel to re
✍ Jacqueline S. Gardner; Cheryl A. Szpunar; Martin J. O'Connell; David P. Facklam; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 652 KB

The Upjohn Consumer Health Survey (UCHS) was a prospective, observational study designed to comply with the US FDA's request that 10,000 users of ROGAINEn (REGAINETM in international markets) Topical Solution 2% (2% minoxidil solution) be systematically studied in the first year following the produc

Determination of the maximum tolerated d
✍ Feig, Stephen A. ;Krailo, Mark D. ;Harris, Richard E. ;Baum, Edward ;Holcenberg, 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

## Abstract An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dos